1 / 1

Metyrapone(Metopirone)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

CAPSULE

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Metyrapone, marketed under the brand name Metopirone, is an adrenal steroid synthesis inhibitor used primarily for the diagnostic evaluation of adrenal insufficiency. It works by inhibiting the 11-beta-hydroxylation reaction in the adrenal cortex, leading to reduced production of cortisol and corticosterone. The drug also stimulates the production of adrenocorticotropic hormone (ACTH) by removing the inhibitory feedback of cortisol.

In clinical practice, Metyrapone is used as part of diagnostic tests to assess adrenal function. It is especially valuable for evaluating patients with suspected adrenal insufficiency. It is administered orally in the form of soft gelatin capsules, typically in a dose of 30 mg/kg (maximum 3 grams), and it is evaluated through measuring 11-desoxycortisol and ACTH levels.

Generic name

Metyrapone(Metopirone)

English name

Metyrapone

Alternative Names

Metopirone

Drug prices

Indications

Metopirone is indicated for use in the diagnosis of adrenal insufficiency in both adult and pediatric patients when combined with other diagnostic tests. It is primarily used for assessing adrenal function, including testing for conditions like Cushing's syndrome and adrenal insufficiency.

Therapeutic Target

adrenal cortex

Active Ingredients

Metyrapone

Dosage form

CAPSULE

specifications

Metopirone is packaged as capsules with a strength of 250 mg per capsule. The exact number of capsules per package is not specified in the document.

Description

Metopirone (Metyrapone) is an oral medication used in diagnostic tests for adrenal insufficiency. It works by inhibiting the enzyme 11β-hydroxylase in the adrenal cortex, thereby reducing cortisol production. This is useful for determining the ability of the adrenal glands to respond to exogenous ACTH (adrenocorticotropic hormone), which is important in diagnosing adrenal disorders.

Dosage and Administration

Single-Dose Short Test:

Dosage: The recommended dose for the Single-Dose Short Test is 30 mg/kg of body weight, administered at midnight.

Administration: The test is performed in combination with other diagnostic assessments. The patient's adrenal response to ACTH should be confirmed before administering Metopirone as a test.

CATEGORY NAVIGATION